Universal Ibogaine Inc. (IBO.V)

CAD 0.02

(0.0%)

Total Liabilities Summary of Universal Ibogaine Inc.

  • Universal Ibogaine Inc.'s latest annual total liabilities in 2022 was 2.37 Million CAD , up 126.62% from previous year.
  • Universal Ibogaine Inc.'s latest quarterly total liabilities in 2023 Q3 was 3.67 Million CAD , up 9.24% from previous quarter.
  • Universal Ibogaine Inc. reported annual total liabilities of 1.04 Million CAD in 2021, up 4723.55% from previous year.
  • Universal Ibogaine Inc. reported annual total liabilities of 21.72 Thousand CAD in 2020, up 8.12% from previous year.
  • Universal Ibogaine Inc. reported quarterly total liabilities of 3.36 Million CAD for 2023 Q2, up 11.07% from previous quarter.
  • Universal Ibogaine Inc. reported quarterly total liabilities of 3.02 Million CAD for 2023 Q1, up 27.55% from previous quarter.

Annual Total Liabilities Chart of Universal Ibogaine Inc. (2022 - 2017)

Historical Annual Total Liabilities of Universal Ibogaine Inc. (2022 - 2017)

Year Total Liabilities Total Liabilities Growth
2022 2.37 Million CAD 126.62%
2021 1.04 Million CAD 4723.55%
2020 21.72 Thousand CAD 8.12%
2019 20.09 Thousand CAD -21.01%
2018 25.43 Thousand CAD 354.23%
2017 5600.00 CAD 0.0%

Peer Total Liabilities Comparison of Universal Ibogaine Inc.

Name Total Liabilities Total Liabilities Difference
Arch Biopartners Inc. 6.68 Million CAD 64.456%
Covalon Technologies Ltd. 6.1 Million CAD 61.121%
Hemostemix Inc. 7.68 Million CAD 69.1%
Kane Biotech Inc. 14.09 Million CAD 83.147%
MedMira Inc. 18.68 Million CAD 87.29%
Marvel Biosciences Corp. 2.39 Million CAD 0.744%
NervGen Pharma Corp. 15.24 Million CAD 84.423%
XORTX Therapeutics Inc. 1.08 Million CAD -118.043%